Data Presented at TCT Reinforce Edwards Lifesciences’ Commitment to Structural Heart Innovation
31 10월 2024 - 5:05AM
Business Wire
Edwards Lifesciences (NYSE: EW) today announced significant
additions to the body of high-quality evidence presented and
published during the Transcatheter Cardiovascular Therapeutics
(TCT) conference, addressing the critical needs of patients with
structural heart disease.
“The data at TCT on Edwards’ innovations underscore our
commitment to scientific leadership and our focus to bring
impactful and life-saving structural heart therapies to patients
and physicians,” said Bernard Zovighian, Edwards’ CEO. “This new
clinical evidence also advances Edwards’ opportunities within both
TAVR and TMTT to treat more patients with our advanced technologies
and support long-term, sustainable growth across the company in the
years ahead.”
The data, including results from the groundbreaking EARLY TAVR
and TRISCEND II trials, highlighted outcomes from studies that
focused on previously understudied patient groups. The findings
emphasized that timely treatment of structural heart disease not
only enhances clinical outcomes and quality of life for patients,
but also reduces long-term healthcare costs.
Transcatheter Aortic Valve Replacement
(TAVR)
New data provided compelling evidence about TAVR, particularly
for patients without symptoms but suffering from severe aortic
stenosis, including:
- A meta-analysis highlighting the importance of early
intervention in asymptomatic severe aortic stenosis patients
and reinforcing the results from the EARLY TAVR trial.
- A pooled analysis of RHEIA + PARTNER 3 data highlighting the
efficacy and safety of Edwards TAVR in women.
- Insights into delays in care for aortic valve replacement
(AVR), finding pre-procedural requirements contribute to TAVR
patients waiting significantly longer than SAVR patients to access
treatment.
- An assessment of the value of timely treatment of aortic
stenosis, finding that intervening at earlier stages of cardiac
damage helps save costs and healthcare resources.
Transcatheter Mitral and Tricuspid
Therapies (TMTT)
Additionally, new evidence was presented on Edwards’ portfolio
of transcatheter mitral and tricuspid repair and replacement
therapies, reinforcing the strength of the company’s innovations
beyond TAVR, including:
- The two-year outcomes from the pivotal CLASP IID trial,
showcasing sustained benefits of PASCAL in treating degenerative
mitral regurgitation in a broad patient population.
- An analysis of the healthcare resource utilization and costs
associated with tricuspid regurgitation, highlighting the
economic impact of timely intervention.
- One-year results from the TWIST global feasibility study,
demonstrating promising outcomes for Innovalve in transcatheter
mitral valve replacement, which was recently acquired by
Edwards.
- Data from the PASTE registry, encompassing more than
1,000 European patients treated with PASCAL in the tricuspid
position, underscoring its safety and effectiveness.
About Edwards
Lifesciences
Edwards Lifesciences is the leading global structural heart
innovation company, driven by a passion to improve patient lives.
Through breakthrough technologies, world-class evidence and
partnerships with clinicians and healthcare stakeholders, our
employees are inspired by our patient-focused culture to deliver
life-changing innovations to those who need them most. Discover
more at www.edwards.com and follow us on LinkedIn, Facebook,
Instagram and YouTube.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
We intend the forward-looking statements contained in this release
to be covered by the safe harbor provisions of such Acts. These
forward-looking statements can sometimes be identified by the use
of forward-looking words, such as “may,” “might,” “believe,”
“will,” “expect,” “project,” “estimate,” “should,” “anticipate,”
“plan,” “goal,” “continue,” “seek,” “intend,” “optimistic,”
“aspire,” “confident” and other forms of these words and include,
but are not limited to, statements made by Mr. Zovighian and
statements regarding expected product benefits, including safety
and efficacy, other benefits including costs and health care
resources, patient outcomes, objectives and expectations and other
statements that are not historical facts. Forward-looking
statements are based on estimates and assumptions made by
management of the company and are believed to be reasonable, though
they are inherently uncertain and difficult to predict. Our
forward-looking statements speak only as of the date on which they
are made, and we do not undertake any obligation to update any
forward-looking statement to reflect events or circumstances after
the date of the statement. Investors are cautioned not to unduly
rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those expressed or
implied by the forward-looking statements based on a number of
factors as detailed in the company's filings with the Securities
and Exchange Commission. These filings, along with important safety
information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, CLASP, CLASP
II, EARLY TAVR, PARTNER, PASCAL, TRISCEND, and TRISCEND II are
trademarks of Edwards Lifesciences Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241030713206/en/
Media Contact: Amy Hytowitz, 949-250-4009 Investor Contact: Mark
Wilterding, 949-250-6826
Edwards Lifesciences (NYSE:EW)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 10월(10) 2024
Edwards Lifesciences (NYSE:EW)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024